Search Results - E. Feist

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Adult Still's disease: New horizons

    Adult Still's disease: New horizons by E. L. Nasonov, E. Feist

    Published 2021-12-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)

    The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6) by E. L. Nasonov, E. Feist

    Published 2022-11-01
    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

    Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor in... by E. Feist, S. Fatenejad, S. Grishin, E. Korneva, M.E. Luggen, E. Nasonov, M. Samsonov, J.S. Smolen, R.M. Fleischmann

    Published 2023-04-01
    Get full text
    Article

    Save to List
    Saved in:
  4. 4
    Mapping the value of commercial fishing and potential costs of offshore wind energy on the U.S: West Coast: Towards an assessment of resource use tradeoffs.

    Mapping the value of commercial fishing and potential costs of offshore wind energy on the U.S: West Coast: Towards an assessment of resource use tradeoffs. by Blake E Feist, Robert Griffin, Jameal F Samhouri, Leena Riekkola, Andrew O Shelton, Y Allen Chen, Kayleigh Somers, Kelly Andrews, Owen R Liu, Jennifer Ise

    Published 2025-01-01
    Get full text
    Article

    Save to List
    Saved in:
  5. 5
    Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)

    Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab) by A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Y. Y. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, I. N. Kushnir, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, P. A. Shesternya, N. V. Yudina, E. Feist, E. L. Nasonov

    Published 2023-06-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: